MRSA Infections in 33 of 491 Division-I Football Players

November 12, 2026

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

Reader question: What did this specific study measure, in whom, at what timepoint—and what would go beyond its evidence?

Study snapshot

Study element	Reported detail
Population	491 players from three Division-I collegiate football programs.
Design	Retrospective consolidated team surveillance of diagnosed MRSA infections, lesion features, treatment and timing.
Comparator	Occurrence was compared by player position, body site and season phase.
Timepoint	Across the observed football seasons, with timing divided by season phase.
Key result	Thirty-three players (6.7%) were diagnosed with MRSA infection. Abscesses accounted for 70%; 90% underwent surgical drainage and 27% received intravenous antibiotics. Infections occurred predominantly in the first third of the season (p<0.001), with no difference by playing position.
Funding/conflict context	The PubMed abstract does not state funding or conflict disclosures. No skincare product was studied.

What was actually measured?

Thirty-three players (6.7%) were diagnosed with MRSA infection. Abscesses accounted for 70%; 90% underwent surgical drainage and 27% received intravenous antibiotics. Infections occurred predominantly in the first third of the season (p<0.001), with no difference by playing position.

The team denominator and timing describe a serious cluster pattern, but the findings concern medical infection control—not ordinary dry-skin care.

The denominator defines the scope. A workplace outbreak, clinic series, questionnaire, case report and long-term cohort answer different questions. Their percentages and odds ratios cannot be silently transferred to another population.

What the result does not prove

Three selected teams, retrospective records, historical MRSA epidemiology, no unexposed control and team-level practices limit current generalization.

Association, timing and biological plausibility can strengthen an occupational interpretation, but observational evidence cannot automatically establish individual causation. Referral patterns, reporting, task mix, protective equipment, nonwork exposures and access to care may all change an estimate.

A PubMed record is a bibliographic source. PubMed indexing is not NIH endorsement of the authors’ conclusions, this interpretation or any product.

Exposure detail matters more than the job label

People with the same title may handle different materials for different durations. Useful documentation identifies the exact product or process, route of contact, glove or PPE material, wetness, friction, heat, dust, splash potential, frequency and how symptoms change away from the task.

A symptom survey can identify a pattern, clinical examination can refine the differential diagnosis, and patch testing can identify delayed sensitization. None alone proves that a workplace material caused an individual condition. Clinical relevance still requires a credible exposure and time course.

Questions worth recording

Which task, product, glove, tool, chemical, plant, dust or surface came before symptoms?
Where did the change begin, and did it improve away from work or after a process or PPE change?
How often were hands wet, washed, disinfected, occluded, rubbed, heated or exposed to cold?
Were labels, ingredients and safety-data sheets reviewed with occupational health?
Did the problem affect dexterity, sleep, pace, attendance, work quality or safety?

Prevention comes before cosmetic care

Substitution, closed systems, local exhaust, splash control, safer cleaning methods, training and correctly selected protective equipment address exposure at its source. Gloves are not automatically protective: material, fit, breakthrough time, sweating, reuse and rubber accelerators all matter.

Do not deliberately place workplace products on skin to test a theory. Persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function warrant professional evaluation.

Primary research and guidance

Where Dr. Arsy #003 fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, neutralizes workplace chemicals, is appropriate for every person, or provides pediatric or 24-hour efficacy.

Continue the evidence series

Evidence note: This educational article separates reported findings from interpretation. It is not a diagnosis, treatment recommendation or workplace-safety determination.

← Back to Doctor's Notes